If you are afraid the market is due for a significant pullback in the near-term, you might be considering moving to cash. However, and depending on your goals, you might instead want to consider the attractive 8.1% dividend yield blue chip stock described in this article. Specifically, no one knows when the next pullback is coming, but the stock described in this report has a very healthy dividend (with over 50 years of dividend increases), and the shares have significantly less volatility risk than the rest of the market (as per its 0.6, 3-year beta). Furthermore, we like the company’s aggressive share repurchase program. In this report, we review the business, valuation, dividend safety and risks, and then conclude with our opinion on who should invest.
Performance Update: Disciplined Growth Portfolio Up Again, S&P 500 Down
After a strong +53.0% gain in 2020, the Blue Harbinger Disciplined Growth portfolio added another 4.2% in January, while the S&P 500 was down 1.0%. In this brief update report, we review the holdings, weightings, price targets and ratings changes for the Disciplined Growth portfolio, as well as the 6.0% yield on the Income Equity strategy.
Powerful Growth Trajectory: This New Value-Based Health-Care Model Company
This recently public company (August 2020) is on a tremendous growth trajectory as it delivers a highly differentiated, technology-enabled, value-based care model for Medicare. The continuing growth opportunities stem from the rapid shift of patients to value-based care and increasing patient consumerism. This report reviews the business, its growth prospects, valuation and risks, and then concludes with our opinion about investing.
NovoCure: Large Opportunities Ahead
NovoCure (NVCR) is a global oncology company with patented “Tumor Treating Fields” (“TTF”) technology. It has multiple programs in phase 2 and phase 3 of clinical trials which can potentially result in exponential revenue growth and Total Addressable Market (“TAM”) expansion. As a result, and due to improving market penetration, the stock more than doubled in 2020. In this report, we review NovoCure’s business model, competitive strengths, financial position and valuation, and then conclude with our opinion on investing from a risk-versus-reward standpoint.
Fiverr: Attractive High-Income Options Trade
Fiverr (FVRR) is a global marketplace connecting freelancers and businesses for their digital service needs. The business was already growing rapidly, and the pandemic accelerated it. The trade in this report generates very high upfront premium income (that you get to keep no matter what) and it gives you a chance to pick up shares of this attractive business at a significantly lower price. The premium income available on this trade is very high because the share price has been volatile, but the business remains attractive in the long-term. We believe this is an attractive trade to place today and potentially over the next few trading sessions as long as the share price doesn’t move too dramatically before then.
Magnite: Massive Total Addressable Market
Magnite is a digital advertising industry company that has made inroads into the fast-growing Connected TV (“CTV”) space (thanks to its April 2020 merger with Telaria). The company is now the world’s largest sell-side platform (“SSP”) for buying and selling advertising inventory available across multiple channels, including mobile, desktop and CTV. Magnite experienced demand erosion in 2020 as the global pandemic resulted in reduced ad spending. However, revenues have started to re-accelerate, and the share price has been rebounding dramatically off 2020 lows. What’s more, there is a massive total addressable market opportunity ahead. In this report, we analyze Magnite’s business model, its market opportunity, challenges, current valuation, and conclude with our opinion on investing (including a specific trading idea).
Pfizer's 4.3% Dividend Yield: Worth a Closer Look
The 4.3% dividend yield of mega-cap pharmaceutical company Pfizer (PFE) is worth a closer look. Specifically, its return on capital is above its cost of capital (a good thing), its margins should increase as a result of the Upjohn spinoff, its covid vaccine is in addition to an already strong core business, it’s paid 328 consecutive quarterly dividend (and has increased the dividend 11 years straight), and the share price just dipped. This article reviews the health of the business, valuation, risks, dividend safety, and concludes with our opinion on investing.
FuboTV: The Ride Will be Bumpy
FuboTV is a “sports first” streaming platform with a very high growth trajectory and a large total addressable market (i.e. lots of room to run). Specifically, it is benefiting from the the secular decline in traditional TV, the shift to connected TV advertising, and the potential growth in online sports wagering. This report reviews the health of the business, growth prospects, valuation, risks and concludes with our opinion on investing.
This Chip Stock: A Rare and Powerful Tech Turnaround
It’s not often that a tech company can successfully reinvent itself considering immense global competition in a rapidly changing marketplace. However, this report covers a semiconductor (chip) company, that has successfully turned itself around and has continuing powerful long-term price appreciation potential ahead. In this report, we take a detailed look at the business, the market opportunity, risks and valuation, and then conclude with our opinion on investing.
Iron Mountain's 8.6% Yield: High Risk, High Reward
Iron Mountain’s 8.6% dividend yield is compelling for some investors but comes with risks. The company remains confident of sustaining the current dividend, but we’ll describe the big risks that investors should consider (such as debt load, lack of growth in its core storage business, and high capital intensity). While the company has taken some measures to counter these risks, it’s prudent for risk-averse investor to understand the risk-reward tradeoff. This report reviews the health of the business, valuation, risks, dividend safety, and concludes with our opinion about investing in Iron Mountain.
Top 10 Big-Dividend REITs: Contrarian Value
2020 was a challenging year for Real Estate Investment Trusts (“REITs”). The sector (as measured by (XLRE)) was down ~3.% (and that includes dividends) as compared to +17.8% for the overall S&P 500 (SPY). And the performance was even more sharply divergent by REIT subsectors (for example, retail REITs performed even worse) versus the tech-heavy Nasdaq (QQQ) for example which gained 48.3% for the year. Obviously, the social-distancing aspects of the terrible coronavirus pandemic had a big impact on market performance, and with the continuing rollout of vaccines there are some reasons for increased optimism. However, the story is much deeper and much more nuanced than that. In this report, we countdown our top 10 big-dividend REITs (starting with #10 and concluding with our top #1 idea), including our careful consideration for current market conditions combined with company-specific opportunities.
Attractively Priced 6.8% Yield REIT CEF (MOPAY)
If you are an income-focused contrarian investor, you may be looking for opportunities among real estate securities, considering this has been one of the worst performing sectors of 2020 and it is know for its attractive dividend yields (and especially considering the potentially positive impacts of the recent coronavirus vaccines). In this report, we review an attractively priced real estate Closed-End Fund (“CEF”) that is able to offer investors a compelling 6.8% yield (paid monthly—MOPAY) thanks to its share price discount versus its net asset value (NAV) and its prudent use of leverage (~23.98%), among other important characteristics.
Vast Growth Opportunity: Newly Public Shares
Shares of this newly public “DevOps” company debuted in September and swiftly traded approximately 100% above the $44 initial public offering price. However, given the impressive high growth rate, product offerings and expanding opportunity in a very large and nascent industry—the shares are worth a closer look (especially considering the share price has been quietly reverting back towards its initial IPO level in recent weeks). In this report, we analyze company’s business model, market opportunity, competitive position, valuation and risks before finally concluding with our opinion on investing.
Attractive 4.0% Dividend Yield Industrial REIT
This report reviews an attractive industrial REIT that will continue to benefit from e-commerce trends. It has maintained or increased its dividend for 29 years in a row and it currently yields ~4.0%. It has the highest occupancy and rent collections in the industrial REIT space (tenants include some of the largest well-know investment grade companies) and the valuation is attractive. It also has multiple growth catalysts. This article reviews the health of the business, valuation, risks, dividend safety, and concludes with our opinion on why it may be worth considering if you are a long-term income-focused investor (that likes growth too).
Safe, Stable, 4.7% Yield REIT, Attractive Sub-Industry
In recent quarters, while real estate sub sectors such as office and retail have struggled as a result of the pandemic, selective industrial REITs have emerged as outperformers primarily because of the growth in e-commerce. For example, the specific industrial REIT we review in this article has consistently expanded its asset base since its IPO in 2011 and is well placed to grow in the years ahead (through planned acquisitions and rental accretions). It also offers a 4.7% dividend yield, paid monthly. In this report, we analyze the company’s income profile, growth as well as dividend prospects and finally conclude with our opinion on investing.
Data Center REIT: Don't Miss This Opportunity to Buy Low
This data center REIT offers an attractive investment opportunity for investors seeking steady income along with long-term capital gains. It has raised its dividend for the past 15 years (it currently yields 3.5%) and is likely to continue to do so given strong industry tailwinds. We think there is a disconnect between business fundamentals and recent the underperformance of the shares (down ~18% over the last two months). This article reviews the health of the business, valuation, risks, dividend safety, and concludes with our opinion about why it’s worth considering if you are a long-term income-focused investor.
Tremendous Growth Potential, Share Price Just Dipped
Some of the best growth opportunities are NOT based in Silicon Valley, and as such they remain undervalued relative to their long-term growth potential. This report highlights one such attractive opportunity that competes with Silicon Valley darling Twilio (TWLO) in the CPaaS market, but trades at a more attractive valuation and offers even higher expected growth. Not to mention its owned IP network provides scalability, reliability, major cost savings and uniquely positions it for success.
PIMCO & DoubleLine CEFs: 9.1% & 7.7% Yields, MOPAY
If it’s mainly big steady income payments you seek, this report reviews two fixed-income closed-end-funds (CEFs) that offer attractive yields of 9.1% and 7.7%, respectively. They both pay monthly (MOPAY), and trade at very attractive prices. This report shares the important details for you to consider.
Unity Software: A Long-Term Winner
Unity Software provides tools to videogame developers. The company recently completed its initial public offering in September. The business is healthy, revenue is growing rapidly, and it has a large total addressable market. In this report, we analyze Unity’s business model, its market opportunity, competitive position, valuation, risks, and finally conclude with our opinion on investing.
Top 10 Big Dividends: Contrarian Value Opportunities
Value and income stocks have been challenged this year as the COVID-19 pandemic has made life difficult for many of them and as many growth and technology stocks have sailed higher. However, if you are a contrarian, there are select opportunities among the wreckage that are absolutely worth considering. Especially as many value and income stocks have started to perk up lately as news of a COVID-19 vaccine is spurring some capitulation between high-flying growth stocks and beaten down value and income names.